Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 12Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Nasopharyngeal Carcinoma 8Esophageal Squamous Cell Carcinoma 7Carcinoma, Non-Small-Cell Lung 6Squamous Cell Carcinoma of Head and Neck 5Small Cell Lung Carcinoma 5Triple Negative Breast Neoplasms 4Recurrence 3Pancreatic Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Neoplasm Metastasis 2Muscle Invasive Bladder Cancer (MIBC) 2Biliary Tract Neoplasms 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Sarcoma 1Salivary Gland Malignant Neoplasms 1SCLC, Extensive Stage 1Rectal Neoplasms 1Rare Tumour 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non-Muscle Invasive Bladder Neoplasms 1Non Squamous Non Small Cell Lung Cancer 1Neoplasms 1NSCLC 1Muscle-invasive Bladder Urothelial Carcinoma 1Melanoma 1Esophageal Neoplasms 1

Interventions

Nivolumab 6pembrolizumab 3Specimen Handling 3Ipilimumab 3relatlimab 2cemiplimab 2Melphalan 2Magnetic Resonance Spectroscopy 2Interleukin-2 2vedolizumab 1trametinib 1toripalimab 1sulforaphane 1gadopiclenol 1famitinib 1anlotinib 1X-Rays 1Watchful Waiting 1Ultraviolet Therapy 1Toll-Like Receptor 1 1Therapeutics 1Temozolomide 1Technetium 1Standard of Care 1Sentinel Lymph Node Biopsy 1SHR-1701 1Rehabilitation 1Phototherapy 1Photopheresis 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Melanoma × toripalimab × Clear all
NCT05539118 2022-09-14

Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma

Xijing Hospital

Phase 1/2 Not yet recruiting
48 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡